1,525 reports of this reaction
2.5% of all BELIMUMAB reports
#6 most reported adverse reaction
HEADACHE is the #6 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 1,525 FDA adverse event reports linking BELIMUMAB to HEADACHE. This represents approximately 2.5% of all 60,128 adverse event reports for this drug.
Patients taking BELIMUMAB who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for BELIMUMAB, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for BELIMUMAB:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,525 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.5% of all adverse event reports for BELIMUMAB, making it a notable side effect.
If you experience headache while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.